学术论文 | 出版专著 | 奖励表彰 | 研究方向 | 招生计划
Lian B#, Li Z#, Wu N, Li M, Chen X, Zheng H, Gao M, Wang D, Sheng X, Tian H, Si L, Chi Z, Wang X, Lai Y, Sun T, Zhang Q, Kong Y, Long GV, Guo J, Cui C*. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.,Annals Of Oncology,2024 Feb;35(2):211-220.
Lian B#, Si L, Chi ZH, Sheng XN, Kong Y, Wang X, Tian H, Li K, Mao LL, Bai X, Tang BX, Yan XQ, Li SM, Zhou L, Dai J, Tang XW, Ran FW, Yao S, Guo J, Cui CL*. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial,Annals of Oncology,2022 Oct; 33 (10): 1061-1070.
L. L. Mao#, B. Lian#, C.L. Li, X. Bai, L. Zhou, C. L. Cui, Z. H. Chi, X. N. Sheng, X. Wang, B. X. Tang, X. Q. Yan, S. M. Li, Y. Kong, J. Dai, X. T. Wei, J. Li, R. Duan, H. Y. Xu, X. W. Wu, Y. Yang, F. Z. Cheng, C. Zhang, F. Z. Xia, Z. Pang, J. Guo*, L. Si*. Camrelizumab plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial,JAMA Oncology,2023 Aug 1;9(8):1099-1107
Chuanliang Cui#,Juan Li#,Yue Yang#, Lu Si, Zhihong Chi, Lili Mao, Xuan Wang, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei,Yuping Shen, Qun Guo, Shirui Zheng, Jun Guo,and Bin Lian*, IBI310 (anti-CTLA-4 antibody) monotherapy or in combination with sintilimab in advanced melanoma or urothelial carcinoma.,The Innovation,2024 May 10;5(4):100638.
Lian B#, Yang Y#, Zheng B, Si L, Zhou L, Chi Z, Mao L, Wang X, Li S, Li J, Wang L, Guo J*, Cui C*. Efficacy and safety of postoperative adjuvant radiotherapy in resected nasal cavity and paranasal sinus mucosal melanoma: A Combined Analysis.,Int J Radiat Oncol Biol Phys,2024 Mar 22:S0360-3016(24)00437-1.
Y. Wang#, B. Lian#, L. Si, L. L. Mao, Z. H. Chi, X. N. Sheng, Y. Kong, X. Wang, X. Bai, X. Q. Yan, S. M. Li, B. X. Tang, J. Dai, L. Zhou, X. T. Wei, C. L. Cui*, J. Guo*. Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I–III,European Journal of Cancer,2022 Nov;175:196-203
C. Cui#, B. Lian#, X. Zhang, D. Wu, K. Li, L. Si, Y. Yang, H. Tian, L. Zhou, Z. Chi, X. Sheng, Y. Kong, L. Mao, X. Wang, X. Bai, X. Yan, S. Li, J. Dai, B. Tang, X. Wei, J. E. Gershenwald, C. M. Balch, J. Guo*. An Evidence-Based staging system for mucosal melanoma: A proposal,Ann Surg Oncol,2022 Aug;29(8):5221-5234
CSCO黑色素瘤诊疗指南2019、2020、2021、2022、2023、2024版, 参编, 人民卫生出版社, 2024.9
《中国恶性肿瘤整合诊治指南》黑色素瘤分册2022版, 参编, 天津科学技术出版社, 2022.6
卫健委黑色素瘤诊疗规范2022版, 参编, 国家卫生健康委员会, 2022.4
《中国抗肿瘤新药临床研究评述》2020、2021版, 参编, 中国医药创新促进会, 2021.9
优秀带教老师, 2022年, 第1完成人, 北京大学肿瘤医院, 2022.12
教学管理先进个人, 2025年, 第1完成人, 北京大学临床肿瘤学院, 2025.5
优秀专科医师指导教师, 2024年, 第1完成人, 北京大学医学部, 2025.1
招生年度 | 招生专业 | 学位级别 | 学位类型 | 研究方向 | 选拔方式 | 操作 |
---|---|---|---|---|---|---|
2026 | 肿瘤学 | 硕士 | 科学学位 | 黑色素瘤的精准治疗和转化研究 | 推荐免试 |
社会任职
- 中国临床肿瘤学会(CSCO)老年肿瘤防治专委会委员
- 中国抗癌协会(CACA)整合肿瘤学分会青年创新联盟委员
- 中国临床肿瘤学会(CSCO)肿瘤心脏病学专委会委员
- 国家肿瘤质控中心黑色素瘤质控专委会委员
- 中国临床肿瘤学会(CSCO)恶性黑色素瘤专委会秘书长
学习、工作经历
- 2023.8.1~,主任医师
- 2023.6.6~,硕士生导师
- 2019.8.1~,副教授
- 2018.8.1~2023.7.31,副主任医师
- 2014.3.15~2014.6.15,Moffitt Cancer Center,高级访问学者